FMP
Hims & Hers Health, Inc.
HIMS
NYSE
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
51.96 USD
0.56 (1.08%)
Historical Prices
From:
To:
About
ceo
Mr. Andrew Dudum
sector
Consumer Defensive
industry
Household & Personal Products
website
https://www.forhims.comexchange
NYSE
Description
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness c...
CIK
0001773751
ISIN
US4330001060
CUSIP
433000106
Address
2269 Chestnut Street
Phone
415 851 0195
Country
US
Employee
1,637
IPO Date
Sep 13, 2019
Financial Statement
Earnings
HIMS Financial Summary
CIK
0001773751
Exchange
NYSE
Industry
Household & Personal...
Sector
Consumer Defensive
CUSIP
433000106
ISIN
US4330001060
Country
US
Price
51.96
Beta
1.85
Volume Avg.
33.95M
Market Cap
11.19B
Shares
-
52-Week
12.07-72.98
DCF
-7.66
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
76.41
P/B
-
Website
https://www.forhims.com
Upgrades and Downgrades
Rating Distribution
TheFly
3 days ago
May 7, 2025
Hold
Hold
TheFly
4 days ago
May 6, 2025
Mixed
Mixed
TheFly
4 days ago
May 6, 2025
Neutral
Neutral
TheFly
4 days ago
May 6, 2025
Sell
Sell
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest HIMS News
Davit Kirakosyan
4 days ago
Hims & Hers Shares Fall 7% on Q1 EPS Miss and Cautious Q2 Fo...
Hims & Hers Health (NYSE:HIMS) reported first-quarter results that showed impressive revenue growth and subscriber expansion but fell short on earnings, with a softer near-term outlook prompting a 7% drop in shares in pre-market today. The telehealth company posted adjusted earnings of $0.20 per share for Q1 2025, below the analyst consensus of $0.23. Revenue surged 111% year-over-year to $586 million, beating expectations of $538.9 million, as the company continues to scale its direct-to-consum...
Andrew Wynn
May 2, 2025
Hims & Hers Health, Inc. (HIMS) Quarterly Earnings and Strat...
Hims & Hers Health, Inc. (NYSE:HIMS) is a telehealth company that focuses on providing personalized healthcare solutions. The company offers a range of services, including sexual health, dermatology, and mental health, which collectively generated over $1.2 billion in sales in 2024. HIMS is set to release its quarterly earnings on Monday, May 5, 2025, with Wall Street analysts estimating earnings per share (EPS) of $0.12 and projected revenue of approximately $538.4 million. The MedTech sector,...
Davit Kirakosyan
Apr 16, 2025
BofA Maintains Bearish Stance on Hims & Hers Amid Signs of S...
BofA Securities reiterated its Underperform rating on Hims & Hers Health (NYSE:HIMS), keeping its price target steady at $22, citing signs of decelerating momentum in the company’s core business. The company’s shares are currently down more than 10% intra-day. Although online revenue in Q1 appears poised to beat consensus estimates—with projections ranging between $567 million and $601 million versus the $528.4 million expected—March data showed a notable slowdown. Year-over-year sales growth dr...
Andrew Wynn
Jan 24, 2025
Hims & Hers Health, Inc. (HIMS) Stock Performance and In...
Hims & Hers Health, Inc. (NYSE:HIMS) is a telehealth company that provides a platform for patients to access prescription medications online. The company has gained attention for offering popular GLP-1 drugs, which are known for aiding weight loss. Despite not manufacturing these drugs, their availability has significantly contributed to HIMS's growth. The company competes in the healthcare sector, facing challenges from increased competition and potential loss of growth catalysts. On January 2...
Davit Kirakosyan
Jan 7, 2025
Hims & Hers Coverage Initiated with Buy Rating on Growth and...
BTIG analysts initiated coverage of Hims & Hers Health (NYSE:HIMS) with a Buy rating and a price target of $35 on the stock. The recommendation highlights the company's innovative approach to delivering healthcare services and its strong growth trajectory. Hims & Hers operates a disruptive, direct-to-consumer business model, offering health services on a subscription basis to over 2 million members—a 44% year-over-year increase as of the third quarter of 2024. The company addresses a wide range ...
The Motley Fool
Aug 22, 2024
What Is Going On With Hims & Hers Stock?
After a strong start to the year, the stock is down 30% since June.
Seeking Alpha
Aug 20, 2024
Hims & Hers Health: GLP-1 Is Not The Only Tailwind In This G...
Hims & Hers Health stock is up over 37% since my initial coverage, as the company is experiencing strong investor optimism from its compounded GLP-1 additions to its Weight Loss portfolio. The company reported its Q2 FY24 earnings where revenue and Adjusted EBITDA grew 52% and 270% YoY respectively, as subscribers opting for Personalized Solutions grew over 164% YoY. While Hims generated close to $15M in Q2 from GLP-1 medications, it is simultaneously innovating and expanding its personalized so...
Seeking Alpha
Aug 20, 2024
Hims & Hers Health: Healthy Gift
Hims & Hers Health, Inc. reported booming sales in Q2, but the stock fell due to possible confusion on compounded GLP-1 drug sales. The online health and wellness platform dramatically hiked Q3 sales targets to over $375 million. The stock would trade at $41 based on trading at just 5x EV/S targets.
